PT  - JOURNAL ARTICLE
AU  - Chan, Lili
AU  - Chaudhary, Kumardeep
AU  - Saha, Aparna
AU  - Chauhan, Kinsuk
AU  - Vaid, Akhil
AU  - Baweja, Mukta
AU  - Campbell, Kirk
AU  - Chun, Nicholas
AU  - Chung, Miriam
AU  - Deshpande, Priya
AU  - Farouk, Samira S.
AU  - Kaufman, Lewis
AU  - Kim, Tonia
AU  - Koncicki, Holly
AU  - Lapsia, Vijay
AU  - Leisman, Staci
AU  - Lu, Emily
AU  - Meliambro, Kristin
AU  - Menon, Madhav C.
AU  - Rein, Joshua L.
AU  - Sharma, Shuchita
AU  - Tokita, Joji
AU  - Uribarri, Jaime
AU  - Vassalotti, Joseph A.
AU  - Winston, Jonathan
AU  - Mathews, Kusum S.
AU  - Zhao, Shan
AU  - Paranjpe, Ishan
AU  - Somani, Sulaiman
AU  - Richter, Felix
AU  - Do, Ron
AU  - Miotto, Riccardo
AU  - Lala, Anuradha
AU  - Kia, Arash
AU  - Timsina, Prem
AU  - Li, Li
AU  - Danieletto, Matteo
AU  - Golden, Eddye
AU  - Glowe, Patricia
AU  - Zweig, Micol
AU  - Singh, Manbir
AU  - Freeman, Robert
AU  - Chen, Rong
AU  - Nestler, Eric
AU  - Narula, Jagat
AU  - Just, Allan C.
AU  - Horowitz, Carol
AU  - Aberg, Judith
AU  - Loos, Ruth J.F.
AU  - Cho, Judy
AU  - Fayad, Zahi
AU  - Cordon-Cardo, Carlos
AU  - Schadt, Eric
AU  - Levin, Matthew A.
AU  - Reich, David L.
AU  - Fuster, Valentin
AU  - Murphy, Barbara
AU  - He, John Cijiang
AU  - Charney, Alexander W.
AU  - Böttinger, Erwin P.
AU  - Glicksberg, Benjamin S.
AU  - Coca, Steven G.
AU  - Nadkarni, Girish N.
AU  - ,
TI  - Acute Kidney Injury in Hospitalized Patients with COVID-19
AID  - 10.1101/2020.05.04.20090944
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.04.20090944
4099  - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090944.short
4100  - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090944.full
AB  - Importance Preliminary reports indicate that acute kidney injury (AKI) is common in coronavirus disease (COVID)-19 patients and is associated with worse outcomes. AKI in hospitalized COVID-19 patients in the United States is not well-described.Objective To provide information about frequency, outcomes and recovery associated with AKI and dialysis in hospitalized COVID-19 patients.Design Observational, retrospective study.Setting Admitted to hospital between February 27 and April 15, 2020.Participants Patients aged ≥18 years with laboratory confirmed COVID-19Exposures AKI (peak serum creatinine increase of 0.3 mg/dL or 50% above baseline).Main Outcomes and Measures Frequency of AKI and dialysis requirement, AKI recovery, and adjusted odds ratios (aOR) with mortality. We also trained and tested a machine learning model for predicting dialysis requirement with independent validation.Results A total of 3,235 hospitalized patients were diagnosed with COVID-19. AKI occurred in 1406 (46%) patients overall and 280 (20%) with AKI required renal replacement therapy. The incidence of AKI (admission plus new cases) in patients admitted to the intensive care unit was 68% (553 of 815). In the entire cohort, the proportion with stages 1, 2, and 3 AKI were 35%, 20%, 45%, respectively. In those needing intensive care, the respective proportions were 20%, 17%, 63%, and 34% received acute renal replacement therapy. Independent predictors of severe AKI were chronic kidney disease, systolic blood pressure, and potassium at baseline. In-hospital mortality in patients with AKI was 41% overall and 52% in intensive care. The aOR for mortality associated with AKI was 9.6 (95% CI 7.4-12.3) overall and 20.9 (95% CI 11.7-37.3) in patients receiving intensive care. 56% of patients with AKI who were discharged alive recovered kidney function back to baseline. The area under the curve (AUC) for the machine learned predictive model using baseline features for dialysis requirement was 0.79 in a validation test.Conclusions and Relevance AKI is common in patients hospitalized with COVID-19, associated with worse mortality, and the majority of patients that survive do not recover kidney function. A machine-learned model using admission features had good performance for dialysis prediction and could be used for resource allocation.Question What is incidence and outcomes of acute kidney injury (AKI) in patients hospitalized with COVID-19?Findings In this observational study of 3,235 hospitalized patients with COVID-19 in New York City, AKI occurred in 46% of patients and 20% of those patients required dialysis. AKI was associated with increased mortality. 44% of patients discharged alive had residual acute kidney disease. A machine learned predictive model using baseline features for dialysis requirement had an AUC Of 0.79.Meaning AKI was common in patients with COVID-19, associated with increased mortality, and nearly half of patients had acute kidney disease on discharge.Competing Interest StatementGNN, CH, BM, SGC receive financial compensation as consultants and advisory board members for RenalytixAI, and own equity in RenalytixAI. BM is a non-executive director of RenalytixAI. In the past 3 years, SGC has also received consulting fees from CHF Solutions, Takeda Pharmaceuticals, Relypsa, Bayer, Goldfinch Bio, Boehringer-Ingelheim, and inRegen. In the past 3 years GNN has also received consulting fees from AstraZeneca, Reata, GLG Consulting, BioVie and grant support from Goldfinch Bio. K.S.M. is supported by K23HL130648 from the National, Heart, Lung, and Blood Institute.Funding StatementGNN is supported by a career development award from the National Institutes of Health (NIH) (K23DK107908) and is also supported by R01DK108803, U01HG007278, U01HG009610, and U01DK116100. SGC is supported by the following grants: U01DK106962, R01DK115562, R01HL085757, U01OH011326, R01DK112258, and RRTI UG 2019.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A